Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

- PMLiVE

Amgen’s Kyprolis approved in Europe

Multiple myeloma drugwins licence three years after gaining US approval

Sanofi reception

Sanofi and AstraZeneca agree massive compound swap deal

Will exchange over 200,000 compounds in a new open innovation collaboration

Eli Lilly HQ

Sanofi and Lilly highlight rheumatoid arthritis hopefuls at ACR

Top-line results for sarilumab and baricitinib

Sanofi reception

Sanofi and Lexicon collaborate on new medication for diabetes

Plan to develop new investigational drugsotagliflozin

Sanofi reception

Sanofi and Hanmi collaborate on diabetes treatments

Aims to optimise efficacy of medications

Sanofi reception

Sanofi forges $1.5bn cancer partnership with BioNTech

Set to develop five cancer therapies

EU flag

Celgene’s Vidaza wins wider approval for acute myeloid leukaemia

Elderly patients to gain access to cancer drug

- PMLiVE

Sanofi posts positive data for MS drug Aubagio

Phase III study shows drug slows brain volume loss

- PMLiVE

Express Scripts ‘will pay $750m on PCSK9 inhibitors next year’

Amgen's Repatha and Sanofi's Praluent included

- PMLiVE

Genzyme opts into gene silencing therapy for haemophilia

Interim results show positive benefits for ALN-AT3

Sanofi reception

Sanofi’s lixisenatide is back under FDA review

Brings GLP-1 agonist closer to US market

Eli Lilly HQ

Lilly set to launch Lantus biosimilar in the US next year

Settlement ends the company's legal dispute with Sanofi

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links